Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

Carotid Artery Stenosis Clinical Trial

— C-Guardians  

Official title:

A Multicenter, Single-Arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard™ Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04900844
• Other study ID #: PRO-9017
• Status: Recruiting
• Phase: N/A
• Start date: July 1, 2021
• Est. completion date: October 1, 2025

Study information

• Verified date: June 2022
• Source: InspireMD
• Contact: Christina Brennan
• Phone: 888-776-6804
• Email: christinab[@]inspiremd.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 315
• Est. completion date: October 1, 2025
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

2. Subject is willing and able to take dual antiplatelet therapy for a minimum of 30 days.

3. Life expectancy = 24 months from the date of the index procedure.

4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.

5. Subject has a modified Rankin Score of = 2at the time of informed consent.

6. Subject is diagnosed with carotid artery disease treatable with carotid artery

stenting and is considered high risk for carotid endarterectomy (CEA) as evidenced by:

1. Symptomatic carotid stenosis = 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack (TIA) or stroke within the last 6 months ipsilateral to the side of the stenosis. Or

2. Asymptomatic carotid stenosis = 80%

7. Co-Morbidity High Risk Conditions for CEA, i.e., meets one or more of the following

criteria:

1. Age = 70 (maximum 80 years)

2. CCS angina class 3-4 or unstable angina

3. Congestive Heart Failure (CHF) NYHA class III-IV

4. Left ventricular ejection fraction (LVEF) = 35%

5. MI = 72 hours and < 6 weeks pre-procedure

6. Multi-vessel CAD (= 2 vessels >70% stenosis) and history of angina

7. Chronic Obstructive Pulmonary Disease (COPD) with FEV1<50

8. Permanent contralateral cranial nerve injury/paralysis

9. Restenosis from previous carotid endarterectomy (CEA)

10. Planned coronary artery bypass grafting (CABG) or valve replacement surgery between 31-60 days after CAS

11. Abdominal aortic aneurysm repair or peripheral vascular surgery is planned between 31 to 60 days after CAS. OR

8. High Anatomical Risk for CEA, i.e., meets one or more of the following criteria:

1. Occlusion of the contralateral CCA or ICA.

2. Prior radiation treatment to the neck or a radical neck dissection.

3. Severe bilateral ICA stenosis requiring treatment.

4. Target lesion at or above the level of the jaw (C2) or below the clavicle.

5. Severe tandem lesions

6. Inability to extend the hear due to cervical disorders.

7. Laryngeal palsy or laryngectomy.

8. Prior head and neck surgery in the region of the carotid artery.

9. Tracheostomy or tracheostoma.

10. Spinal immobility of the neck.

11. Hostile neck or surgically inaccessible lesion.

10. Angiographic General Inclusion Criteria, i.e., meets all the following criteria:

1. Target lesion location at the carotid bifurcation and/or proximal internal carotid artery (ICA)

2. Vessel distal to target lesion can accommodate a distal embolic protection device (EPD), and EPD is compatible with CGuard™ device (refer to CGuard™ System IFU for specific EPDs).

3. Target vessel reference diameter at stent landing zone is 4.8 mm to 9.0 mm.

4. Target lesion length = 36 mm, that can be covered by a single CGuard™ stent.

Exclusion Criteria:

1. Planned interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index carotid procedure.

2. Severe vascular anatomy that would preclude safe sheath insertion, deliverability of stent or embolic protection device.

3. Type III or bovine aortic arch.

4. Total occlusion of the target vessel.

5. Presence of "String sign" of the target lesion.

6. In-tandem lesions with >= 50% or >= 80% diameter stenosis for symptomatic or asymptomatic patients, respectively, which cannot be covered by a single CGuard™ stent.

7. History of bleeding diatheses or coagulopathy or inability to accept blood transfusions.

8. Bilateral carotid stenosis requiring treatment on both sides within 30 days prior to or following planned index procedure.

9. Subject is on renal replacement therapy or has Stage 4 or 5 Chronic Kidney Disease (CKD).

10. Known reason for potential stroke other than carotid artery stenosis, including history of atrial fibrillation or other sources of thromboemboli within the past 12 months.

11. History of thrombophilia.

12. Known sensitivity or allergy to nitinol, titanium, heparin, aspirin or other anticoagulant/ antiplatelet therapies.

13. Contrast media sensitivity or allergy that cannot be pre-treated.

14. Previous stent placement in the target vessel.

15. Evolving stroke or intracranial hemorrhage, or history of previous intracranial hemorrhage or brain surgery within the past 12 months.

16. Major neurologic deficit with NIHSS of = 15.

17. Dementia or other neurologic condition confounding the neurologic assessment.

18. Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.

19. Subject previously enrolled in this clinical trial.

20. Possible / probable non-compliance of subject with protocol required follow up or medication.

21. Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this C-GUARDIANS Pivotal IDE Clinical Study.

22. SARS-CoV2 (COVID-19) active infection.

Related Conditions & MeSH terms

• Carotid Artery Stenosis
• Carotid Stenosis
• Constriction, Pathologic

Intervention

Device:
• CGuard Carotid Stent implantation
Implantation of CGuard carotid stent in the eligible patients

Locations

Country	Name	City	State
Poland	Leszek Leic Upper-Silesian Medical Centre of the Silesian Medical University	Katowice
Poland	John Paul II Hospital	Kraków
United States	Ascension Seton, Seton Heart Institute	Austin	Texas
United States	University of Buffalo	Buffalo	New York
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ascension, St. John Hospital	Detroit	Michigan
United States	Prisma Health-Upstate	Greenville	South Carolina
United States	UPMC-Pinnacle	Harrisburg	Pennsylvania
United States	University of Florida	Jacksonville	Florida
United States	Ballad CVA Heart Institute	Kingsport	Tennessee
United States	Turkey Creek Medical Center	Knoxville	Tennessee
United States	Oschner Health	New Orleans	Louisiana
United States	Miriam Hospital	Providence	Rhode Island
United States	Mercy Hospital	Saint Louis	Missouri
United States	Avera Heart Hospital	Sioux Falls	South Dakota
United States	Stony Brook University Hospital	Stony Brook	New York
United States	Novant Health	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
InspireMD

Countries where clinical trial is conducted

United States,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure	The primary endpoint is the composite of the following: Incidence of the following Major Adverse Events: Death (allcause mortality), all Stroke, and Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication OR; Ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC) adjudication.	From index procedure to 1 year follow up
Secondary	Incidence of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years	Incidence of the following composite of Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.	From index procedure to 3 years follow up
Secondary	Incidence of particular components of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years	Incidence of each individual component of the Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.	From index procedure to 3 years follow up
Secondary	Incidence of ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.	Ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.	From index procedure to 3 years follow up
Secondary	Incidence of major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.	Major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.	From index procedure to 3 years follow up
Secondary	Incidence of In-stent Restenosis (ISR) > 70% in ultrasound evaluation	Incidence of In-stent Restenosis (ISR) > 70%. ISR > 70% is defined as PSV > 300 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through; 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.	At 1-, 2-, 3-year post-index procedure follow-up
Secondary	Incidence of In-stent Restenosis (ISR) > 50% in ultrasound evaluation	Incidence of In-stent Restenosis (ISR) > 50%. ISR > 50% is defined as PSV > 220 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through; 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.	At 1-, 2-, 3-year post-index procedure follow-up
Secondary	Incidence of target lesion revascularization	Incidence of Target Lesion Revascularization (TLR) through 1-,2,3-year follow-up. TLR is defined as clinically driven revascularization procedure of the original treatment site, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase the luminal diameter within the stented lesion or within 5 mm proximal or distal to the index stent.	At 1-, 2-, 3-year post-index procedure follow-up
Secondary	Composite of Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events	Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events from discharge up to 1-,2- and 3-year follow-up.	From index procedure to 3 years follow up
Secondary	Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure for subjects that adhere to antiplatelet pharmacology.	Primary endpoint for subjects that adhere to antiplatelet pharmacology.	From index procedure to 1 year follow up